Scarica l'app Stockscreener
6.63
6.36%
-0.45
Dopo l'orario di chiusura:
6.63
Niagen Bioscience Inc Borsa (NAGE) Ultime notizie
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® - MarketScreener
H.C. Wainwright holds $11 target on Niagen Bioscience stock By Investing.com - Investing.com South Africa
H.C. Wainwright holds $11 target on Niagen Bioscience stock - Investing.com
A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE) - simplywall.st
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) - MarketScreener
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results - MarketScreener
Niagen Bioscience broadens NAD+ precursor IP portfolio with new patent - TipRanks
Niagen Bioscience secures new patent for NAD+ precursors - Investing.com
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms - Business Wire
Niagen Bioscience, Inc. Rings the Closing Bell - Nasdaq
ChromaDex Completes Name Change to Niagen Bioscience -March 19, 2025 at 09:29 am EDT - Marketscreener.com
Chromadex Rebrands to Niagen Bioscience, Inc. - TipRanks
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science - The Bakersfield Californian
ChromaDex changes name to Niagen Bioscience to home in on healthy aging - SupplySide Supplement Journal
Chromadex’s Strategic Rebranding and Promising Clinical Developments Justify Buy Rating - TipRanks
ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+ - HBW Insight
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 - Bluefield Daily Telegraph
Major Rebrand: ChromaDex Evolves to Niagen Bioscience, Sharpens Focus on Aging Science - Stock Titan
Healthy Aging Leader ChromaDex Takes Center Stage at ROTH Conference Longevity Panel - Stock Titan
ChromaDex Capitalizes On Longevity Boom, But Valuation Remains High - Seeking Alpha
ChromaDex Reports Strong 2024 Financial Performance - TipRanks
When Will ChromaDex Reveal Its Q4 Performance? Key Date for NAD+ Leader's Financial Results - Stock Titan
ChromaDex to Present at Lytham Partners Healthcare Summit, Showcasing NAD+ Research Advances - StockTitan
Daré Bioscience, Inc. and ARPA-H Ring the Nasdaq Stock Market Closing Bell - Nasdaq
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide - Business Wire
Thorne acquires brain health formula partner in $5 million deal - SupplySide Supplement Journal
The proper role of pre-blends of nutrients in production of dietary supplements - SupplySide Supplement Journal
FDA Criminal Office Said to Be Examining Drug Ostarine in Dietary Supplements - SupplySide Supplement Journal
Technology disruption in the dietary supplement industry - SupplySide Supplement Journal
IV and Injection Offerings to Additional Leading Wellness Clinics - Business Wire
GMP Requirements for Softgels - SupplySide Supplement Journal
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions - Business Wire
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs) - Business Wire
ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award - Business Wire
is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program - Business Wire
ChromaDex sides with FDA, pharma in NMN supplements debate - SupplySide Supplement Journal
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen - Business Wire
Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+ - PR Newswire
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients - Business Wire
ChromaDex and Zesty Paws team up on cellular health for dogs - Longevity.Technology
(Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD - Business Wire
ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line - Business Wire
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NM - Business Wire
ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness - Business Wire
Better gummies with Chelamax® magnesium – infographic - SupplySide Supplement Journal
Transcript : ChromaDex Corporation, Q1 2023 Earnings Call, May 10, 2023 - Marketscreener.com
ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States - Business Wire
ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards - Business Wire
How This Global Bioscience Company Got Innovative With Research And Saved Millions - Forbes
ChromaDex and Nestlé Health Science Announce New Niagen - Business Wire
ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen - Business Wire
Longevity supplements report: ChromaDex profile - Longevity.Technology
Exclusive: ChromaDex’s CEO on Longevity commercialisation - Longevity.Technology
Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College - Business Wire
Greg Arabatzis, ChromaDex - WholeFoods Magazine
ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen - Business Wire
HC Wainwright Adjusts Price Target on ChromaDex to $7 From $8, Reiterates Buy Rating - MarketScreener
ChromaDex stock gains postmarket on JV to distribute supplement in China - Seeking Alpha
ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen - Business Wire
ChromaDex External Research Program (CERP ) Celebrates Over 250 Research Agreements With 235+ Researchers Around the World - Business Wire
ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio - BioSpace
Nasdaq firm backed by ‘Superman’ Li eyes China’s market for supplements - South China Morning Post
Jury verdict tilts toward Elysium Health in dispute with ChromaDex, court records show - SupplySide Supplement Journal
'Get Rid of the Scumbags': Trade Secrets Battle Between ChromaDex, Elysium Offers Rare Look Inside Major Life Science Companies - Law.com
ChromaDex Supplement Tru Niagen Now Available at Walmart - Los Angeles Business Journal
ChromaDex and Walmart Launch Tru Niagen® in 3,800 Walmart Stores Across the United States - Business Wire
ChromaDex Growth Story Just Getting Started: Interview With CEO Rob Fried (NASDAQ:CDXC) - Seeking Alpha
ChromaDex Announces Retail Distribution of Tru Niagen® in Walmart Stores Across the United States - Business Wire
ChromaDex Announces $25 Million Private Placement of Common Stock - Business Wire
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):